Table 3.
Laboratory parameters following therapy for severe COVID-19 a
| Parameter | Control group (n = 71) | Ribavirin group (n = 44) | P-value |
|---|---|---|---|
| Haemoglobin (g/L) | 115.8 ± 19.8 | 116.0 ± 16.7 | 0.952 |
| Haemoglobin change (g/L) | –10.4 ± 12.6 | –5.3 ± 13.5 | 0.051 |
| Leukocyte count (× 109/L) | 6.4 ± 3.6 | 5.7 ± 3.0 | 0.283 |
| Lymphocyte count (× 109/L) | 1.1 ± 0.6 | 1.1 ± 0.5 | 0.720 |
| C-reactive protein (mg/L) | 39.1 ± 48.1 | 28.2 ± 37.9 | 0.233 |
| Platelet count (× 109/L) | 243.3 ± 103.8 | 263.4 ± 128.2 | 0.367 |
| Serum creatinine (μmol/L) | 69.7 ± 26.8 | 63.3 ± 21.4 | 0.195 |
| BUN (mmol/L) | 5.8 ± 4.3 | 4.4 ± 2.7 | 0.068 |
| ALT (U/L) | 62.1 ± 187.3 | 35.8 ± 17.7 | 0.372 |
| AST (U/L) | 56.9 ± 145.9 | 34.3 ± 21.7 | 0.327 |
COVID-19, coronavirus disease 2019; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a
Data are presented as the mean ± standard deviation.